JSM 2011 Online Program

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.


517 *	Wed, 8/3/2011, 10:30 AM - 12:20 PM	CC-D235
Topics in Group Sequential Designs and Interim Analysis — Contributed Papers
Biopharmaceutical Section
Chair(s): Samir Lababidi, U.S. Food and Drug Administration
10:35 AM	Software Applications to Group Sequential Trial Design and Monitoring — Li Zhu, Amgen Inc. ; Liyun Ni, Amgen Inc. ; Bin Yao, Amgen Inc.
10:50 AM	Considerations on Decision Rules for Futility Based on Multiple Studies — Annpey Pong, Merck & Co., Inc. ; Jun Zhao, Merck & Co., Inc.
11:05 AM	Optimal Designs with Futility Stopping for Diagnostic Imaging Studies — Aida Aydemir, Bayer HealthCare Pharmaceuticals Inc. ; Igor Zurbenko, The State University of New York at Albany ; Daniel Haverstock, Bayer HealthCare Pharmaceuticals Inc. ; Christoph Gerlinger , Bayer Schering Pharma AG
11:20 AM	Group Sequential Tests of Futility: The Relationship Between Type II Error Spending and Conditional Power Approaches — Thomas W. Dobbins, Merck & Co., Inc.
11:35 AM	Futility Analysis Approaches in Clinical Equivalence Trials — Christine K. Gause, Merck Research Laboratories
11:50 AM	Blind Review of Planned Analyses for Clinical Trials — Lan Liu, Quintiles Inc. ; John Schollenberger, Quintiles Inc.
12:05 PM	Floor Discussion

2011 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.